A study protocol for the treatment of relapsed and refractory B-cell lymphoma of the central nervous system with abutinib combined with TEDD-R regimen

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100045519

Enrollment

Unknown

Registered

2021-04-18

Start date

2021-04-19

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

relapsed and refractory CNS B-cell lymphoma

Interventions

Therapy group:Obitinib + chemotherapy (TEDDI-R) regimen

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Aged >=18 years; 2.Histologically diagnosed as B-cell lymphoma, primary or secondary to the central nervous system; 3.Relapsed and refractory patients; 4.Patients who have not previously received BTK inhibitors.

Exclusion criteria

Exclusion criteria: 1.There are active infections that are not controlled; 2.Combined with other malignant tumors; 3.Severe liver insufficiency; 4.Platelets are less than 30 x 10^9/L.

Design outcomes

Primary

Measure	Time frame
The overall response rate (ORR) during induction of remission;	—

Secondary

Measure	Time frame
1-year overall Survival (OS) security;1-year progression-free survival (PFS);Safety data;	—

Countries

China

Contacts

Public ContactHu Kai

Beijing Boren Hospital

huk@borenhospital.com+86 15010390336

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026